IgG4 but no IgG1 antibody production after intralymphatic immunotherapy with recombinant <scp>MAT</scp>‐Feld1 in human

Freiberger, Sandra N.; Zehnder, Meret; Gafvelin, Guro; Grönlund, Hans; Kündig, Thomas M.; Johansen, Pål

doi:10.1111/all.12946

Cited by 29 publications

(27 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In NAPTs, nasal reactivity to HDM allergens was decreased after ILIT as previously described 12356. Furthermore, the serum levels of allergen-specific IgE and IgG 4 to Df and Dp were increased 4 months after ILIT, being consistent with the results of previous studies 2314. However, these levels were again decreased 1 year after ILIT.…”

Section: Discussionsupporting

confidence: 90%

“…However, these levels were again decreased 1 year after ILIT. Previous studies have reported decreased allergen-specific IgE levels 3 years after ILIT1 and decreased allergen-specific IgG 4 levels 1 year after ILIT 14. Regarding dog and cat allergens, we failed to observe any significant change in the level of allergen-specific IgE or IgG 4 , due to an inadequate number of subjects.…”

Section: Discussioncontrasting

confidence: 81%

See 1 more Smart Citation

A Pilot Study of Intralymphatic Immunotherapy for House Dust Mite, Cat, and Dog Allergies

Lee

Choi

Joe

et al. 2017

Allergy Asthma Immunol Res

View full text Add to dashboard Cite

Several recent clinical trials reported that intralymphatic immunotherapy (ILIT) for some allergens, such as cat dander and pollen, induce tolerance more rapidly than conventional subcutaneous or sublingual immunotherapy, have a comparable duration of effect after only 3 injections, and do not provoke serious local or systemic reactions. However, the efficacy and safety of ILIT are using Dermatophagoides farinae (Df), Dermatophagoides pteronyssinus (Dp), and dog, which are indoor allergens that are commonly found globally, need to be evaluated. Furthermore, use of multiple allergens in ILIT should be investigated. We assessed the clinical efficacy and adverse effects of ILIT using aqueous Df, Dp, dog, and cat allergens or mixtures thereof in patients with allergic rhinitis. A total of 11 subjects with AR sensitized to Df, Dp, cat, and/or dog allergens received 3 intralymphatic inguinal injections of sensitized allergen extract (HollisterStier, New Orleans, LA, USA). Clinical parameters were assessed before ILIT, and 4 months and 1 year after the first injection. Rhinitis symptoms were alleviated and quality of life was improved 4 months after ILIT (P=0.012 and P=0.007, respectively), and these improvements lasted for 1 year after ILIT (P=0.047 and P=0.009, respectively). However, we observed 2 cases of anaphylaxis, one case of a moderate-to-severe systemic hypersensitivity reaction and the other case of a severe local reaction at the injection site after ILIT. In conclusion, ILIT can rapidly improve allergy symptoms and quality of life, and this effect lasts for 1 year. In hypersensitized patients, however, ILIT can provoke severe systemic and/or local hypersensitivity reactions when performed using aqueous allergen extracts.

show abstract

Section: Discussionsupporting

confidence: 90%

Section: Discussioncontrasting

confidence: 81%

A Pilot Study of Intralymphatic Immunotherapy for House Dust Mite, Cat, and Dog Allergies

Lee

Choi

Joe

et al. 2017

Allergy Asthma Immunol Res

View full text Add to dashboard Cite

show abstract

“…Also, ILIT has been successfully performed in various animal species, such as mice, rats, dogs, horses, ponies, cows, and monkeys, as reviewed previously [28]. When analysing human sera after ILIT with MAT-Fel d 1, Freiberger et al [29] recently found that the predominant immunoglobulin subclass was IgG4, whereas only marginal levels of IgG1, IgG2, and IgG3 were induced. We previously showed that this predominant IgG4 induction correlated with the allergen-specific IL-10-producing T cell response [13].…”

Section: Ilit Updatedmentioning

confidence: 99%

Intralymphatic Immunotherapy: Update and Unmet Needs

Senti

Freiburghaus

Larenas‐Linnemann

et al. 2018

Int Arch Allergy Immunol

View full text Add to dashboard Cite

Allergen-specific immunotherapy (AIT) is the only allergy treatment that confers long-term symptom amelioration for patients suffering from allergy. The most frequently used allergen application route is subcutaneous injection (SCIT), commonly taken as the gold standard, followed by sublingual (SLIT) or oral (OIT) application of allergen preparations. This is an up-to-date review of the clinical evidence for a novel route of allergen application, i.e., directly into lymph nodes – intralymphatic immunotherapy (ILIT). The major advantages of ILIT over the current AIT approaches are its short duration and the low allergen doses administered. The whole treatment consists of merely 3 ultrasound-guided injections into inguinal lymph nodes 1 month apart. While the number of patients included in randomised controlled trials is still limited, the clinical results for ILIT are encouraging, but more clinical trials are needed, as well as more preclinical work for optimising formulations.

show abstract

“…In addition, a study employing a nonclassical allergen intralymphatic immunotherapy using a modular antigen transporter Fel d 1 (MAT-Fel d 1) has found a strong increase in allergenspecific IgG4 levels and some increase in IgG2 antibody subclasses, but this procedure was not able to stimulate the production of IgG1 and IgG3 subclasses [58].…”

Section: Immunotherapy Follow-upmentioning

confidence: 99%

Allergen-Specific Immunotherapy Follow-Up by Measuring Allergen-Specific IgG as an Objective Parameter

Taketomi¹,

Miranda²,

Júnior³

et al. 2017

Immunotherapy - Myths, Reality, Ideas, Future

View full text Add to dashboard Cite

The clinical efficacy of the allergen-specific immunotherapy (AIT) has been well-documented using inhalant or hymenoptera-derived allergens in atopic patients with corresponding specific IgE antibodies. AIT is considered as the unique treatment that is capable of modifying the natural course of the allergic disease because it induces a variety of immunological mechanisms, with emphasis in the production of blocking IgG antibodies by IL-10-stimulated B cells due to the generation of Treg, Breg, or even Th2 cells. Thus, the measurement of specific IgG subclasses, particularly IgG4, to the crude extract or more importantly to allergen components, might be a useful and potential tool to follow-up objectively the patients undergoing AIT in addition to clinical parameters. In this chapter, the authors have emphasized a very sensitive and highly specific reverse ELISA, developed by them, to measure IgG subclasses directed to clinically relevant natural allergens that are undoubtedly better when compared to those obtained with recombinant counterparts. Such a technique may produce more authentic results taking into account the IgG subclass binding capacity to a particular allergen and might be a valuable and alternative method for monitoring activation of tolerance-inducing mechanisms in patients under AIT.

show abstract

IgG4 but no IgG1 antibody production after intralymphatic immunotherapy with recombinant MAT‐Feld1 in human

Cited by 29 publications

References 28 publications

A Pilot Study of Intralymphatic Immunotherapy for House Dust Mite, Cat, and Dog Allergies

A Pilot Study of Intralymphatic Immunotherapy for House Dust Mite, Cat, and Dog Allergies

Intralymphatic Immunotherapy: Update and Unmet Needs

Allergen-Specific Immunotherapy Follow-Up by Measuring Allergen-Specific IgG as an Objective Parameter

Contact Info

Product

Resources

About